CA1224418A - Therapeutic compositions for oral use containing stable s-adenosyl-l-methionine salts - Google Patents
Therapeutic compositions for oral use containing stable s-adenosyl-l-methionine saltsInfo
- Publication number
- CA1224418A CA1224418A CA000460360A CA460360A CA1224418A CA 1224418 A CA1224418 A CA 1224418A CA 000460360 A CA000460360 A CA 000460360A CA 460360 A CA460360 A CA 460360A CA 1224418 A CA1224418 A CA 1224418A
- Authority
- CA
- Canada
- Prior art keywords
- same
- salts
- therapeutic compositions
- gastro
- adenosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 11
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical class O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- -1 polysiloxanes Polymers 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 18
- 230000000202 analgesic effect Effects 0.000 abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
- 230000001741 anti-phlogistic effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000206575 Chondrus crispus Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000000793 phophlogistic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 101150037155 torY gene Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22621A/83 | 1983-08-24 | ||
| IT22621/83A IT1169772B (it) | 1983-08-24 | 1983-08-24 | Composizioni terapeutiche per uso orale contenenti sali stabili della s-adenosil-l-metionina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1224418A true CA1224418A (en) | 1987-07-21 |
Family
ID=11198524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000460360A Expired CA1224418A (en) | 1983-08-24 | 1984-08-03 | Therapeutic compositions for oral use containing stable s-adenosyl-l-methionine salts |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0136464B1 (en, 2012) |
| JP (1) | JPS6072815A (en, 2012) |
| AT (1) | ATE38151T1 (en, 2012) |
| AU (1) | AU563762B2 (en, 2012) |
| CA (1) | CA1224418A (en, 2012) |
| DE (1) | DE3474774D1 (en, 2012) |
| IT (1) | IT1169772B (en, 2012) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3678643D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Partikel mit konstanter wirkstofffreisetzung. |
| DE3678644D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung. |
| DE3678641D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Partikel mit konstanter wirkstofffreisetzung. |
| WO1988002629A1 (en) * | 1986-10-16 | 1988-04-21 | American Health Products Corporation | 2',3'-didesoxyadenosine composition |
| GB8900812D0 (en) * | 1989-01-14 | 1989-03-08 | Univ Manchester | Pharmaceutical method and compositions |
| IT1229479B (it) * | 1989-03-13 | 1991-09-03 | Bioresearch Spa | Impiego di 5' deossi 5' metiltioadenosina, di s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a favorire la crescita dei capelli in soggetti affetti da calvizie e composizioni farmaceutiche relative. |
| US6759395B2 (en) | 2000-12-18 | 2004-07-06 | Orchid Chemicals & Pharmaceuticals, Ltd. | Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same |
| WO2002049637A1 (en) * | 2000-12-18 | 2002-06-27 | Orchid Chemicals And Pharmaceuticals Limited | A novel soft-gelatin capsule comprising s-adenosylmethionine and a method for producing the same |
| EP1325740B1 (en) | 2001-12-12 | 2004-04-21 | Chemistry & Health International B.V. | Stable granulates containing S-Adenosylmethionine and process for the preparation thereof |
| CN101677543A (zh) * | 2007-01-31 | 2010-03-24 | 甲基化物科学国际有限公司 | S-腺苷甲硫氨酸的延时释放药物制剂 |
| EP2193787A1 (en) | 2008-12-02 | 2010-06-09 | Giorgio Stramentinoli | Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use |
| US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| EA201100309A1 (ru) * | 2011-03-03 | 2011-08-30 | Екофарм Патент Менеджмент Аг | Фармацевтическая композиция, стимулирующая биосинтез s-аденозилметионина, и пероральное лекарственное средство |
| KR20160094451A (ko) | 2012-10-17 | 2016-08-09 | 메틸레이션 사이언시즈 인터내셔널 에스알엘 | S-아데노실메티오닌 및 갈산 에스테르가 포함된 조성물 |
| WO2024238657A2 (en) | 2023-05-15 | 2024-11-21 | Bonafide Health, Llc | Sleep-improving compositions and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR221676A1 (es) * | 1974-07-12 | 1981-03-13 | Bioresearch Sas | Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico |
| JPS5347536A (en) * | 1976-10-12 | 1978-04-28 | Abbott Lab | Pharmaceutical composition for treatment of fertile skin disease |
| JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
| IT1137892B (it) * | 1981-08-24 | 1986-09-10 | Bioresearch Srl | Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo |
-
1983
- 1983-08-24 IT IT22621/83A patent/IT1169772B/it active
-
1984
- 1984-08-01 EP EP84109110A patent/EP0136464B1/en not_active Expired
- 1984-08-01 DE DE8484109110T patent/DE3474774D1/de not_active Expired
- 1984-08-01 AT AT84109110T patent/ATE38151T1/de not_active IP Right Cessation
- 1984-08-03 CA CA000460360A patent/CA1224418A/en not_active Expired
- 1984-08-23 AU AU32326/84A patent/AU563762B2/en not_active Ceased
- 1984-08-24 JP JP59175325A patent/JPS6072815A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ATE38151T1 (de) | 1988-11-15 |
| JPH0531524B2 (en, 2012) | 1993-05-12 |
| IT1169772B (it) | 1987-06-03 |
| JPS6072815A (ja) | 1985-04-24 |
| EP0136464A2 (en) | 1985-04-10 |
| IT8322621A0 (it) | 1983-08-24 |
| AU563762B2 (en) | 1987-07-23 |
| DE3474774D1 (en) | 1988-12-01 |
| AU3232684A (en) | 1985-02-28 |
| EP0136464B1 (en) | 1988-10-26 |
| EP0136464A3 (en) | 1985-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1224418A (en) | Therapeutic compositions for oral use containing stable s-adenosyl-l-methionine salts | |
| EP0697859B1 (en) | Stable, ingestable and absorbable nadh and nadph therapeutic compositions | |
| LV12399A (lv) | Uzlabotas vienreiz diena lietojamas pulsejosas miniciklina mogades sistemas | |
| EP2379062A1 (en) | Pharmaceutical composition comprising one or more fumaric acid esters | |
| HU226689B1 (en) | Use of dialkylfumarates for producing pharmaceutical compositions for the treatment autoimmune diseases | |
| JPH05294831A (ja) | 内服用新規医薬製剤 | |
| EP0724441A1 (en) | Picosulphate dosage form | |
| PT91705B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo farmacos inibidores de ace | |
| JPS6011888B2 (ja) | リウマチ疾患治療薬 | |
| CA3009332A1 (en) | Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof | |
| UA58565C2 (uk) | Ін'єкційний лікувальний засіб "цитофлавин", який має цитопротекторну дію | |
| RU2240784C1 (ru) | Лекарственное средство на основе арбидола | |
| FI89240C (fi) | Anvaendning av tillsatsmedel foer oekning av ibuprofens absorptionshastighet | |
| JPH059116A (ja) | ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤 | |
| JPS6031810B2 (ja) | 静細胞的に活性なアルキル化剤の解毒 | |
| UA12297U (en) | Matrix tablet providing for delayed release of trimetasin | |
| RU2247561C1 (ru) | Комбинированная фармацевтическая композиция с противотуберкулёзным действием | |
| IE46241B1 (en) | Process for the preparation of antidiarrheal agents | |
| RU2254862C1 (ru) | Твердая лекарственная форма хондроитина сульфата | |
| Kavanagh et al. | Heparin by inhalation | |
| JPS6281309A (ja) | バルプロ酸ナトリウム徐放錠 | |
| JPH0466529A (ja) | 細胞変性抑制並びに臓器毒性軽減剤 | |
| GB2179255A (en) | Inhibition of parathyroid hormone secretion | |
| Ko | Renal Action of Raclopride, a Dopamine D2 Receptor Antagonist, in Dog | |
| Hur et al. | Neuroprotective and Neurotrophic Effect of a Novel Quinic Acids derivative Isolated from Aster Scaber |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |